While keep­ing eye on snap NASH OK, In­ven­ti­va tests out al­ter­na­tive PhI­II path

As promis­ing late-stage da­ta rein­vig­o­rate the en­thu­si­asm for NASH drugs af­ter years of set­backs, one play­er is chang­ing up its Phase III plans to cap­i­tal­ize …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER